Detalles de la búsqueda
1.
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
Int J Mol Sci
; 23(16)2022 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36012390
2.
Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes.
Mod Pathol
; 31(2): 299-306, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28984296
3.
A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study.
Oncology
; 95(1): 8-12, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29587278
4.
Experience with eribulin in triple-negative metastatic breast cancer: case studies.
Future Oncol
; 14(7s): 13-20, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29611754
5.
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
Breast Cancer Res
; 15(5): R98, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24148581
6.
Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Oncology
; 83(4): 228-33, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22907070
7.
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.
Biomedicines
; 10(10)2022 Sep 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36289681
8.
Outcome of small invasive breast cancer with no axillary lymph node involvement.
Breast J
; 17(1): 32-8, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21129091
9.
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.
Eur J Cancer
; 144: 224-231, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33373867
10.
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Oncology
; 79(1-2): 98-104, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21079407
11.
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.
BMC Cancer
; 10: 136, 2010 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-20385028
12.
Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer.
Int J Gynecol Cancer
; 20(1): 164-72, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20057287
13.
Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer.
Oncology
; 76(2): 133-41, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19174612
14.
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Front Oncol
; 9: 1124, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31737566
15.
Targeted treatment approaches in refractory germ cell tumors.
Crit Rev Oncol Hematol
; 143: 130-138, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31634730
16.
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Front Oncol
; 9: 1178, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31750258
17.
Proliferation determined by ki67 marker and pCR in locally advanced breast cancer patients treated with neo-adjuvant chemotherapy.
Breast J
; 19(6): 685-6, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24118566
18.
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Clin Transl Oncol
; 10(10): 646-53, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18940745
19.
Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer.
Breast Care (Basel)
; 13(4): 277-283, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30319330
20.
Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.
Oncotarget
; 9(41): 26406-26416, 2018 May 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-29899867